This groundbreaking initiative expands the science of targeted medicine. The study of biomarkers creates the potential to individualize medical treatment by determining how a drug works in the body and identifying patients likely to respond to targeted medicines and therapies.
Sarcopenia is common among older adults, resulting in serious consequences such as disability, increased mortality, and negative effects on co-morbid conditions. It is currently unrecognized as a disease state within the healthcare industry because there is a lack of uniform criteria for its diagnosis and severity.
